Hypothesis

Emodin, by inhibiting EGFR/MAPK signaling, alters the phosphorylation state and adaptor function of p62/SQSTM1, shifting the hierarchical order of selective autophagy toward ubiquitinated anti‑apoptotic proteins (e.g., BCL‑2, BCL‑XL) in senescent cells. This reprogrammed cargo prioritization triggers senolysis without requiring bulk autophagy induction.

Mechanistic Rationale

• EGFR inhibition reduces downstream ERK activity, which has been shown to phosphorylate p62 at Ser403 and modulate its ubiquitin‑binding affinity [Emodin anti‑inflammatory action via EGFR inhibition]; altered phosphorylation can change p62’s preference for specific ubiquitin chain types or cargo adapters.
• In senescent cells, anti‑apoptotic BCL‑2 family members are often ubiquitinated and earmarked for selective autophagy [p62/SQSTM1 functions as a selective autophagy receptor]; a change in p62 selectivity could preferentially degrade these survival factors.
• Precedent exists for compounds that upregulate SQSTM1 and redirect autophagy to degrade specific inflammatory mediators [CpdA upregulates SQSTM1 and induces autophagy]; emodin may act similarly but via EGFR‑dependent signaling rather than direct transcriptional upregulation.
• Disrupting the normal hierarchy of autophagy—where damaged mitochondria are cleared first—could lead to accumulation of deleterious organelles, thereby lowering the threshold for apoptosis when anti‑apoptotic shields are removed.

Testable Predictions

1. Emodin treatment will decrease ERK1/2 phosphorylation and increase p62 Ser403 dephosphorylation in senescent human fibroblasts.
2. Proteomic analysis of ubiquitinated cargos isolated via p62 pull‑down will show enrichment of BCL‑2/BCL‑XL peptides after emodin exposure, while mitochondrial cargo (e.g., TOM20) remains unchanged or depleted later.
3. Senolytic efficacy of emodin (measured by viability loss and SASP reduction) will be attenuated by p62 knock‑down or by expressing a phosphorylation‑mimetic p62(S403D) mutant that restores wild‑type cargo preference.
4. Co‑treatment with lysosomal inhibitors (chloroquine) will block emodin‑induced cell death, confirming dependence on autophagic flux rather than caspase‑8‑mediated extrinsic apoptosis.
5. In BRAF‑V600E senescent melanoma cells, emodin will synergize with low‑dose afatinib to enhance clearance, reflecting convergent EGFR pathway modulation.

Experimental Approach

• Cell models: IR‑induced senescent human IMR‑90 fibroblasts and oncogene‑induced senescent melanoma A375(BRAF‑V600E) lines.
• Treatments: Emodin (10‑25 µM) ± EGFR inhibitor afatinib (1 µM) for 24‑48 h; controls include vehicle and known senolytic (navitoclax).
• Readouts: Western blot for p‑ERK, total ERK, p62, p‑p62(Ser403), LC3‑II/I, and cleaved caspase‑3; flow cytometry for Annexin V/PI; ELISA for SASP factors (IL‑6, IL‑8).
• Selective autophagy assay: Streptavidin‑pull‑down of biotin‑ubiquitin conjugates followed by mass spectrometry to quantify cargo specificity.
• Genetic manipulation: siRNA against p62; CRISPR knock‑in of p62(S403D) and (S403A) mutants.
• Statistical analysis: Two‑way ANOVA with post‑hoc Tukey test; n ≥ 3 biological replicates.

If emodin’s senolytic action hinges on reprogrammed p62 hierarchy rather than generic autophagy activation, then altering p62’s phosphorylation status should decouple EGFR inhibition from cell death, falsifying the hypothesis. Conversely, observing a shift in cargo preference correlated with senolysis would support a novel mechanism linking EGFR signaling to the selective autophagy “cannibalism ritual” that governs cellular survival decisions.